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Introduction
Factor VII activating protease (FSAP), official gene name is hyaluronic acid binding protein 2 (HABP2), is a circulating plasma serine protease with multifunctional properties. The cellular effects of FSAP range from the regulation of growth factor activity 1 , endothelial permeability 2 , nucleosome release 3 , histone inactivation 4 , cell survival 5 and cancerous transformation of cells 6 . In addition to activating factor VII, FSAP has also been shown to activate pro-urokinase as well as inactivate tissue factor pathway inhibitor (TFPI) 7 indicating a role in coagulation and fibrinolysis 8 . Genetic epidemiological studies have shown that the G534E single nucleotide polymorphism (SNP) in the FSAP gene, also called the Marburg I (MI) polymorphism (rs7080536), is found in approximately 5% of Caucasians and is associated with advanced carotid stenosis 9 and stroke 10 . Interestingly, MI-FSAP has about a 5-fold lower proteolytic activity towards all substrates tested and thus represents a loss-of-function polymorphism 11 . In a previous study, we showed that the application of exogenous wild type (WT)-FSAP, but not MI-FSAP, around the dilated artery was able to inhibit neointima formation and SMC proliferation 12 .
Conversely, in FSAP -/mice, neointima formation, leukocyte accumulation, and SMC proliferation were significantly enhanced 13 .
Although the human genetic data on MI-SNP and studies on FSAP -/mice indicate a role for FSAP in vascular proliferative diseases, the mechanism of action of FSAP is still obscure. Does FSAP activate specific receptors and signal transduction mechanisms in cells and are these involved in the pathophysiology of FSAP? In an earlier study it was suggested that protease activated receptors (PARs) were involved in regulating microvascular permeability by FSAP 2 ; the endogenous FSAP expression was inhibited in pulmonary microvascular endothelial cells and this in turn M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 was shown to alter endothelial permeability in the presence of hyaluronic acid in a PAR-dependent manner. We have shown that PAR1 is also a receptor for FSAP in astrocytes and neurons using a low MW antagonist of PAR1 5 . Proteolytic inhibition of platelet-derived growth factor (PDGF)-BB is another possible mechanism of action of FSAP on vascular smooth muscle cells (VSMC) 12 . Similarly, modulation of growth factor activity of fibroblast growth factor (FGF2) or the activation of the bradykininkallikrein system 1 in EC has been proposed.
To further characterize the cellular effects of FSAP on vascular cells, we have performed Affymetrix microarray-based mRNA expression analysis to describe the pattern of gene expression in EC and VSMC. A gene expression profile that is related to inflammation, apoptosis and cell growth was activated in response to FSAP. This regulation of gene expression required the proteolytic activity of FSAP and MI-FSAP did not possess this activity. There were also associated changes in cytokine secretion in response to stimulation with FSAP. In VSMC a PAR-1-dependent mechanism was evident but this was not the case in EC. These results provide a comprehensive insight into the cellular signal transduction pathway mediated by FSAP in vascular cells and will help to explain the role of FSAP in athero-thrombotic diseases.
Materials and methods

Materials:
The isolation of FSAP from human plasma and the preparation of D-phenylalanylprolyl-arginyl chloromethylketone (PPACK)-FSAP has been described before 14 .
Human plasma thrombin was from Sigma Aldrich (Oslo, Norway). PAR1 inhibitors Vorapaxar (SCH530348) and SCH79797 were purchased from Axon Medchem (Groningen, The Netherlands), PAR2 inhibitor (ENMD-1068) was from Enzo Life Sciences (Lörrach, Germany), inhibitor of cAMP, RP-8-Br-cAMPS from BIOLOG Life Science Institute (Bremen, Germany), p38 inhibitor SB203580, ERK1/2 inhibitor PD98059 as well as UO126, AKT inhibitor LY29004 and PDGFβR inhibitor AG1296 were all obtained from Merck-Millipore (Oslo, Norway). All inhibitors were prepared in DMSO to the highest possible concentration.
Preparation of serine protease domain (SPD) of FSAP:
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Cell culture:
Primary human carotid artery vascular smooth muscle cells (VSMC) and human umbilical vein endothelial cells (EC) were obtained from Promocell (Heidelberg, Germany) and cultured in the medium supplied by the manufacturer, Basal Smooth Muscle cell Medium-2 and Endothelial Cell Basal Medium-2, respectively. A total of 4 different isolates of VSMC and 3 different isolates of EC were used for these studies.
Microarray analysis:
VSMC and EC were serum-starved overnight and stimulated with FSAP (10 µg/ml) for 4 or 10 h in duplicate. RNA was isolated and Affymetrix GeneChip Human Gene 1.0 st arrays were used for transcriptome analysis according to the manufacturer's instructions. Data were analyzed using the RMA algorithm and using DNAStar Arraystar software to calculate mean values for the groups, fold changes and Student's t-test p-values with or without Bonferroni and Benjamini-Hochberg correction for multiple testing. Microarray data has been submitted to ArrayExpress (http://www.ebi.ac.uk/arrayexpress) with the following reference number, E-MTAB-5592.
RNA isolation and qPCR analysis:
Total RNA was extracted using total RNA Miniprep Kit from Sigma-Aldrich. Reverse transcription was performed using High Capacity cDNA Reverse Transcription Kit plot was monitored over 40 cycles and continuous fluorescence measurement indicated mRNA expression of analyzed genes. Following amplification, the accuracy of amplicons was confirmed by melting curve analysis and products were run on agarose gels to determine their size. Fluorescent threshold cycles (ct) were set and normalized against ct of the reference gene GAPDH and have been adjusted for individual primer efficiencies as described before 15 . Primer sequences are provided in Supplementary Table 1 .
IL6 and IL8 ELISA:
Serum-starved VSMC or EC were incubated with FSAP at various concentrations and harvested at different time points. Cell supernatants were collected, centrifuged and kept at -40°C until further use. Supernatants were assayed for secreted IL6 and IL8 using human ELISA kits (ImmunoTools, Friesoythe, Germany) according to manufacturer's instructions. Streptavidin-HRP (Dako, Glostrup, Denmark) and 1step TM Ultra TMB, ELISA (Thermo Scientific, Oslo, Norway) was used for detection.
Statistical analysis:
Statistical significance was analysed by the non-parametric Kurskal-Wallis followed by Dunn's post-test (Graphpad Prism, SanDiego, CA). Except the microarray experiment, which was performed as a single independent experiment in duplicate, all other experiments were replicated in 3-6 independent experiments. Composite data from all independent replicates or data from a single experiment is shown as indicated in the figure legend. Data is shown as mean + SEM and significance is denoted by * in case p< 0.05.
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Results
FSAP stimulates inflammation, proliferation and apoptosis-related genes in VSMC and EC:
VSMC and EC were stimulated with human plasma-purified FSAP for 4 and 10 h. The mRNA expression analysis using whole genome microarray identified AREG, PTGS2 and IL6 as up-regulated genes in VSMC and in EC these were SELE, IL8 and VCAM1. Lists of the strongly regulated genes can be found in the Supplementary Tables 2 and 3 . These changes were statistically significant using the Student's t test but not when the Bonferroni and Benjamini-Hochberg corrections for multiple testing were applied. Further, functional annotation analysis using DAVIDv6.8 16 showed that the up-regulated genes could be categorized into inflammation, growth regulation, proliferation and intracellular signalling in VSMC and inflammation, chemotaxis and cytokine cell signalling in EC (Supplementary Tables 4   and 5 ). The terms that described the down-regulated genes in VSMC belonged to the group of aldo/keto reductases that metabolise a variety of endogenous and exogenous substrates (Supplementary Table 6 ). Down regulated genes in EC belonged to groups involved in the regulation of cell cycle and cytoskeleton (Supplementary Table 7 ). Considering the previously known functions of FSAP in athero-thrombosis we centred our further investigations on the up-regulated genes.
These data were further consolidated using real time qPCR. Based on preliminary studies to determine the optimal time point, dose response analysis was performed at 4 h. FSAP mediated a statistically significant increase in expression of AREG and PTGS2 but not IL6 in VSMC (Fig. 1A) . In EC, VCAM1 was induced significantly by FSAP but this was not the case for SELE and IL8 even though the levels of the latter two genes were elevated ( Fig. 1B) . We next studied if FSAP was M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 10 also able to increase protein levels of some of the induced genes. Using an ELISA we observed that secreted IL6 was increased both in a time ( Fig. 1C ) and dose dependent ( Fig. 1D ) manner in VSMC but these changes were not statistically significant. In EC, IL8 secretion was increased is a statistically significant manner by FSAP ( Fig. 1E and F) . Taken together, we identified significant changes in expression of genes which, in certain cases, also matched alterations at the protein level.
FSAP-mediated gene expression requires proteolytic activity:
The cellular effects of hemostasis proteins can be dependent or independent of their protease activity. Aprotinin, a known inhibitor of FSAP, diminished the FSAPinduced gene expression of AREG, IL6 and PTGS2 in VSMC ( Fig Supplementary Fig. 1 ).
The recombinant serine protease domains of WT-FSAP and the MI-isoform
were expressed in bacteria and their activity was determined by cleavage of chromogenic peptide substrate and their purity was determined by gel electrophoresis ( Supplementary Fig. 2 ). The WT protease domain could activate the expression of IL6 and PTGS2, analogous to full length plasma FSAP in VSMC but not of AREG. The MI-isoform, which only differs by one amino acid, did not influence expression of the investigated genes (Fig. 3A) . In EC, the WT-isoform increased the
expression of VCAM1 and IL8, but the 3-fold increase in SELE was not significant.
The MI-isoform had no effect on the expression of SELE and IL8, but it consistently induced VCAM1 in EC (Fig. 3B ). In VSMC, IL6 secretion was stimulated by WT but not the MI-isoform and the same pattern was observed in EC for IL8 ( Fig. 3C and D) .
This demonstrates that only proteolytically active FSAP stimulates a specific gene expression pattern in VSMC and EC whereas this was, generally, not the case for MI-FSAP.
Role of PAR1 in mediating the effects of FSAP on VSMC and EC:
The FSAP-induced expression of AREG and IL6 in VSMC was reversed by the PAR1 inhibitor vorapaxar ( Fig. 4A and B ). Similar results were obtained with another PAR1 antagonist, SCH79797, but not with the PAR2 antagonist ENMD-1068 ( Supplementary Fig. 3 ). Substantial mRNA levels of PAR1 and PAR3 but lower levels of PAR2 and PAR4 were expressed in VSMC (Supplementary data Fig. SIV) . The effect of FSAP on AREG expression was compared to thrombin, which is a prototypic protease agonist known to stimulate gene expression in these cells via PAR1. In VSMC the effect of thrombin (1 U/ml) was comparable to that of FSAP in AREG expression ( Fig. 4C and D) . Vorapaxar also inhibited the effect of thrombin as would be expected ( Fig. 4C and D) . These results clearly identify PAR1, in contrast to PAR2, as an essential FSAP receptor in VSMC that mediates the effects of FSAP on gene expression. EC expressed predominantly PAR1 at the mRNA level ( Supplementary Fig. 4 ).
The effect of FSAP on EC was not inhibited by vorapaxar, even though the effect of thrombin was clearly blocked by this inhibitor (Fig. 5 ). In EC thrombin was about 40-
fold more active than FSAP in IL-8 expression thus FSAP was much weaker agonist on EC indicating a different mechanism of action compared to VSMC.
Activation of gene expression by FSAP through the MAPK and cAMP pathway in VSMC:
In order to get some orientation regarding which pathways may be involved in the regulation of gene expression by FSAP in VSMC we screened various pathway inhibitors. FSAP-induced changes in the expression of AREG and IL6 were used as read-outs. LY294002 (Akt inhibitor), AG1296 (PDGFR inhibitor), SB203580 (P38 MAPK inhibitor) had no effect (data not shown). But, RP-8-Br-cAMP (cAMP inhibitor), PD98059, UO126 (both ERK1/2 inhibitors, of which UO126 is not shown) were all inhibitory (Fig. 4) . The use of these generic pathway inhibitors indicates that complex signal transduction pathways are responsible for changes in gene expression, something that needs to be studied in more detail at a mechanistic level. Because of the smaller changes in gene expression by FSAP in EC, and stronger effects of these pathway inhibitors on basal expression, no specific conclusions could be reached about the pathways involved in EC.
Discussion
Pathway analysis of the regulated genes showed that overwhelmingly proinflammatory genes (SELE, VCAM1, CXCL1, ICAM1 and IL8) were induced in EC and carotid stenosis 9 as well as investigations in knockout mice indicating a role for endogenous FSAP in stroke 5 and neointima formation 13 . Thus, these results provide a basis for a further mechanistic understanding of the role of FSAP in vascular biology.
The differences in gene expression were significant when using a Student's t test; however, when corrections were made for multiple testing, e.g., Benjamini-Hochberg or Bonferroni correction there was a loss of significance due to overcorrection. Thus, the microarray screen was used to identify potentially important changes in gene expression and to identify common regulatory mechanisms for these genes. These results were then further consolidated using qPCR and ELISA. In addition, some genes were detected by multiple probe-sets on the arrays and there was very high reproducibility between these internal replicates confirming the technical reliability of these results.
The specificity of these effects of FSAP on gene expression was established in different ways; the effects of FSAP were inhibited by aprotinin and could not be replicated with the pre-inhibited PPACK-FSAP. This was further verified as recombinant WT FSAP could reproduce these effects, but not the MI-FSAP isoform which had a single amino acid mutation only. Some of the effects of the recombinant proteins did not show the expected pattern for reasons that are not immediately clear at the moment. Thus, a proteolysis-based cellular signalling mechanism of FSAP seems likely, which is unlike some factors e.g., urokinase 18 that can activate cells in a non-proteolytic manner.
We have previously demonstrated that the lack of endogenous FSAP, in FSAP -/mice, seems to promote an inflammatory state by recruiting leukocytes into areas of tissue injury and remodelling 13 and some anti-inflammatory. This duality is also true for the receptor PAR1, which is responsible for pro-and anti-inflammatory effects at the same time. Thrombin stimulates apoptosis in EC via PAR1, but another protease APC is a potent inhibitor of apoptosis through cleavage of PAR1 at a different site 19 . Correspondingly, stimulation of PAR1 can lead to vasodilation or vasoconstriction in the vasculature depending on whether the target cells are EC or VSMC 20 . This duality is also observed for some of the genes induced by FSAP, e.g. IL6 21 and PTGS2 22 . Although, PTGS2 is considered to be mainly a pro-inflammatory gene, its inhibition leads to more atherosclerosis 22 . Similarly, blocking IL6 also revealed a role in inhibiting metabolic inflammation 23 . Thus, the induction of IL6 and PTGS2 in VSMC in vitro may in fact account for anti-inflammatory effects of FSAP that are evident in vivo.
Thus, the pro-and anti-inflammatory effects of FSAP and the differences in vitro and
in vivo need to be evaluated in a context-dependent manner.
In EC, pro-inflammatory genes such as SELE, VCAM1 and IL8 were induced by FSAP, but this effect could not be blocked by PAR1 antagonist. Thrombin's effect on expression of the same genes was stronger and could be completely inhibited by the PAR1 antagonist indicating the presence of functional PAR1 on these cells and the validity of using the PAR1 antagonist. Further preliminary studies on EC showed that thrombin induced a rapid transient increase in intracellular Ca 2+ which was completely absent in FSAP-stimulated cells (data not shown). A previous study has shown that PAR1 and PAR3 are involved in mediating the effects of endogenous We did not detect any FSAP encoding transcripts in the EC used in the current study (data not shown), so the different conclusions may be related to the use of different cells and read-outs. Although, PAR3 is expressed by VSMC at the mRNA level, we did not investigate their role in further detail because the lack of established inhibitors 24 . In an earlier report the activation of bradykinin-and FGF2-dependent signalling pathways by FSAP has been reported in EC 1 and these, rather than PAR1, are more likely to be responsible for the effects of FSAP on gene expression in EC.
In VSMC, mRNA levels of PAR1 were much higher than that of PAR2 and also only the PAR1 inhibitor, but not PAR2 inhibitor, could block the effects of FSAP on gene expression in VSMC. The effects of FSAP and thrombin on gene expression in VSMC were quite comparable but thrombin was far more potent on EC compared to FSAP. The greater effectiveness of FSAP in activating PAR1 in VSMC may be related to the repertoire of co-receptors or receptor dimerization that is specific to VSMC and not found in EC. Thus, VSMC is another cell type, in addition to astrocytes and neurons 5 , where we have observed a PAR1-dependent effect of FSAP. Further investigations are needed to determine where and how PAR1 is cleaved by FSAP and which co-receptors are required for receptor activation.
In the inhibitor screen with various generic pathway inhibitors, a strong inhibitory effect of cAMP antagonist on FSAP-mediated gene expression in VSMC was identified. This seems to be in line with the fact that the expression of IL6 in VSMC was shown to be guided through the cAMP responsive element (CRE) 25, 26 , and CREB phosphorylation in response to FSAP has been demonstrated before in EC 1 . The inhibitory effect of PD98059 is in line with our earlier observations that there is a weak activation of ERK1/2 phosphorylation by FSAP in VSMC 14 -Proteolytically inactive and Marburg I isoform of FSAP had no effect on cells.
-Some, but not all, effect of FSAP were mediated through PAR-1. 
